Last updated: July 30, 2026

ORTHO-NOVUM 10/11-28 market dynamics and financial trajectory (pricing, volume, exclusivity, and competitive risk)

ORTHO-NOVUM 10/11-28 is a combination oral contraceptive (ethinyl estradiol and norethindrone components) whose market trajectory is governed by (1) long-cycle demand stability typical of branded contraceptives, (2) rapid generic erosion after approvals, (3) payer step edits driven by formulary cost containment, and (4) patent and exclusivity timelines that determine when lower-cost entrants can move from “authorized generic” to competitive shelf share. Financially, the product profile aligns with low-to-mid brand revenue longevity rather than high-growth cash generation, with margin compression as generics expand and channel mix shifts toward lower net price equivalents.

Because ORTHO-NOVUM 10/11-28 is an established marketed product and this prompt does not include jurisdictional filing identifiers (FDA application numbers), Orange Book listing keys, NDC-level mapping, or any audited financial statements, no complete, citation-backed market share, revenue, or net pricing series can be produced without risking factual errors.

Is ORTHO-NOVUM 10/11-28 a brand still protected from generics? What patents protect it?

Featured snippet answer: The practical market structure for older combined oral contraceptives is that patents and any remaining exclusivities (if any) are typically narrow to specific formulations, manufacturing, packaging, or use claims, while the active ingredient class is usually broadly generic. For ORTHO-NOVUM 10/11-28 specifically, generic availability and authorized-generic penetration are the key determinants of net sales trajectory rather than premium brand pricing.

What drives “protected vs. generic” status for oral contraceptives?

Patent scope: composition of matter vs method-of-use vs formulation or manufacturing claims.
Regulatory protection: application-specific exclusivity windows (if any) tied to a specific NDA/BLA or supplement.
FDA market entry mechanics: Paragraph IV challenges for ANDAs (often not the main determinant for long-market products).
Channel contracting: PBM formularies and pharmacy distribution terms often force net price to converge toward generic benchmarks.

What to check for ORTHO-NOVUM 10/11-28

FDA Orange Book listing for the exact strength(s), dosage form, and active ingredient mapping.
NDC-to-application crosswalk to ensure the correct listing is reviewed.
Patent list completeness: drug substance and drug product patents, with expiration dates and claim types.

When does ORTHO-NOVUM 10/11-28 lose exclusivity? What is the patent expiration timeline?

Featured snippet answer: For established oral contraceptive brands, exclusivity loss usually translates into a stepped or accelerated net price decline, with volume erosion depending on formulary placement, pharmacy switching, and substitution rules.

Typical exclusivity-to-revenue pattern

Pre-loss period: brand retains some premium placement via contracting.
First generic wave: authorized generics and “typical” generics compress net price.
Subsequent waves: additional ANDAs and pack-size entries further reduce net revenue per unit.
Ongoing: brand revenue persists if brand remains on at least one meaningful formulary tier or if switching barriers remain (patient prescriber preferences, substitution rules, and stock continuity).

How many generic competitors target ORTHO-NOVUM 10/11-28? What generic entry risks exist?

Featured snippet answer: The main “generic entry risk” for ORTHO-NOVUM 10/11-28 is not a single binary event. It is repeated price and access pressure as more ANDAs secure supply, and as PBMs update tiering and prefer other low-cost products.

Generic entry channels that matter

ANDA launches that bring multiple manufacturers and pack sizes.
Authorized generic strategies that reduce branded “floor price” without changing therapeutic coverage.
State-level substitution patterns that shift pharmacy fulfillment from branded to generic.

Commercial risk drivers for the incumbent

Formulary tier movement: preferred to non-preferred increases substitution.
Net price resets in response to wholesale and PBM contracting.
Margin squeeze from rebates and promotional allowances, even when unit demand holds.

What is the Orange Book status of ORTHO-NOVUM 10/11-28 (NDA/ANDA, listed patents, and exclusivity blocks)?

Featured snippet answer: Orange Book status is the operational map for market exclusivity and patent barriers. For this specific product, the exact NDA number, listed patents, and expiration dates must be pulled from the Orange Book listing keyed to the product’s active ingredient and dosage form.

Why Orange Book status controls market dynamics

It determines whether future generic approvals are blocked pending litigation or expiration.
It shapes the Paragraph IV litigation probability and settlement structure.
It informs whether the incumbent can defend shelf placement or rely on non-IP barriers (contracts and patient continuity).

What patent litigation affects ORTHO-NOVUM 10/11-28? Are there settlements or Paragraph IV cases?

Featured snippet answer: For many long-established oral contraceptive brands, major litigation activity occurs earlier in the brand lifecycle. If any litigation remains, it tends to be narrow to specific packaging, dosing regimens, or incremental formulations rather than blocking the active ingredient class indefinitely.

Litigation outcomes that change revenue quickly

30-month stay outcomes that delay generic shelf entry.
Settlements that define “design-around” dates and launch carve-outs.
Court rulings that remove barriers and trigger immediate generic substitution.

How does ORTHO-NOVUM 10/11-28 compare with competing oral contraceptives on market access and pricing?

Featured snippet answer: In oral contraception, comparative advantage usually comes from payer placement and total cost positioning more than clinical differentiation. Competitors with stronger formulary placement or lower net cost capture switchable volume.

Competitive positioning factors

Preferred tier placement at PBMs and large payers.
Contracting strategies that keep branded net cost near generic parity.
Product format and regimen familiarity that reduce prescriber switching.

Common competitor set (therapeutic, not claim scope)

Other combined oral contraceptives using ethinyl estradiol and norethindrone variants.
Lower-cost equivalents with broader manufacturer supply.
Pack-size and dosing-regimen variants that align with payer benefit design.

What formulations are protected by patents for ORTHO-NOVUM 10/11-28?

Featured snippet answer: If patents protect ORTHO-NOVUM 10/11-28 beyond the active ingredient, the likely protected elements are drug product formulation characteristics, manufacturing process steps, or specific dosing schedules.

Formulation-level protection typical for oral contraceptives

Tablet composition and excipient selections.
Stability, dissolution, and manufacturing controls.
Packaging and regimen-specific manufacturing methods.

How do manufacturing and IP barriers affect generic supply for ORTHO-NOVUM 10/11-28?

Featured snippet answer: For oral contraceptives, manufacturing and scale typically define speed of generic uptake once regulatory barriers clear. IP barriers that delay entry create a short window of brand price support, but the longer-term impact comes from supply readiness and contracting.

Barriers that slow or accelerate generic penetration

Quality/CMC readiness for ANDAs.
Ability to source drug substances and maintain stability specs.
Supply chain and pack-size scaling to meet payer demand.

What is the FDA regulatory path impact on ORTHO-NOVUM 10/11-28 market dynamics?

Featured snippet answer: For established combination oral contraceptives, generic products usually follow ANDA pathways. Regulatory path affects timeline to entry through approval readiness and whether any exclusivity or patent prevents approval.

Key regulatory mechanisms

505(b)(2) vs ANDA applicability for incremental changes.
Exclusivity and patent listing constraints by NDA/BLA supplement.
Labeling alignment and bioequivalence consistency.

Revenue exposure: What portion of ORTHO-NOVUM 10/11-28 sales is most at risk from generics and formulary switches?

Featured snippet answer: Revenue exposure is primarily at risk from net price compression and tier downgrades, which often occur without large unit drops initially. Over time, volume erodes as switching accelerates and pharmacies default to preferred generics.

What typically happens after generic entry

Net price declines faster than total units.
Rebates and contracting incentives increase to maintain shelf and prescriber behavior.
Brand market share stabilizes only if branded net cost remains competitive within a payer’s preferred generic set.

Key takeaways

ORTHO-NOVUM 10/11-28’s market dynamics are dominated by generic substitution and payer formulary strategy, not by durable premium pricing.
Financial trajectory for established oral contraceptives typically shows margin compression after generic and authorized-generic expansion, with slower unit erosion depending on tier placement and switching barriers.
Exact exclusivity, patent expiration, litigation status, and Orange Book constraints must be keyed to the specific FDA listing for ORTHO-NOVUM 10/11-28 to quantify the timing of erosion events.

FAQs

1) What typically causes net price declines for older branded oral contraceptives like ORTHO-NOVUM 10/11-28?
Formulary tier changes, PBM contracting resets, and increased generic plus authorized-generic competition.

2) Does ORTHO-NOVUM 10/11-28 revenue fall immediately after generic approval?
Often net price drops first; volume erosion usually follows as switching and pharmacy defaults intensify.

3) Are biosimilars relevant to ORTHO-NOVUM 10/11-28 competition?
No. This product is an oral contraceptive small molecule combination, not a biologic.

4) Which data sources best quantify the market trajectory for ORTHO-NOVUM 10/11-28?
FDA Orange Book for IP barriers; NDC billing and wholesaler/channel data for unit and net price trend; payer formularies and PBM drug lists for access changes.

5) How do settlement agreements affect branded contraceptive shelf retention?
Settlements can define launch dates and design-around timing, which shifts when net price resets become irreversible.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA).

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	219
DailyMed Link:	ORTHO-NOVUM 10/11-28 at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Janssen	ORTHO-NOVUM 10/11-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	018354-002	Jan 11, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ORTHO-NOVUM 10/11-28 Drug Patent Profile

When do Ortho-novum 10/11-28 patents expire, and when can generic versions of Ortho-novum 10/11-28 launch?

AI Deep Research

Questions you can ask:

Summary for ORTHO-NOVUM 10/11-28

US Patents and Regulatory Information for ORTHO-NOVUM 10/11-28